Fig. 6
From: Deletion of MAPL ameliorates septic cardiomyopathy by mitigating mitochondrial dysfunction
MAPL promotes SUMOlyation of drp1 in SCM. A. The protein levels of SUMO1 in mitochondria of shNC- and shMAPL-cardiomyocytes after LPS (20 µg/ml) treatment were detected by western blot (*P < 0.05, ***P < 0.001, n = 5 repeated experiments). B. The protein levels of SUMO1 in mitochondria of heart tissues from mice after sham or CLP challenge were detected (*P < 0.05, **P < 0.01, n = 5 for each group). C-F. Whole lysates of heart tissues or H9C2 cardiomyocytes after CLP challenge or LPS treatment were immunoprecipitated and then immunoblotted with antibodies against the indicated proteins. n = 3 repeated experiment. G. The protein level of MAPL and drp1 in human valve tissues were detected by western blot (***P < 0.001, ****P < 0.0001, n = 3 for each group). H. Schematic diagram of this study. Deficiency or knockdown alleviates SCM by reducing drp1-SUMOylation as well as drp1-mediated mitochondrial dysfunction and cardiomyocyte apoptosis